Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2009 Oct 27.
Published in final edited form as: Tetrahedron Lett. 2008 Oct 27;49(44):6282–6285. doi: 10.1016/j.tetlet.2008.08.052

A New Antimalarial Polyether from a Marine Streptomyces sp. H668

MinKyun Na a,b, Damaris AF Meujo a, Dion Kevin a, Mark T Hamann a,*, Matthew Anderson c, Russell T Hill c,*
PMCID: PMC2577051  NIHMSID: NIHMS71286  PMID: 19865468

Abstract

The antimalarial guided fractionation of the culture of marine Streptomyces sp. strain H668 led to the isolation of a new polyether metabolite. The structure was determined by comprehensive NMR and MS assignments. This new metabolite showed in vitro antimalarial activity against both the chloroquine-susceptible (D6) and -resistant (W2) clones of Plasmodium falciparum, without cytotoxicity to normal cells (Vero) making it a promising first lead from this marine bacterium.


Malaria is a tropical infection caused by four different species of protozoa from the genus Plasmodium transmitted to humans by the Anopheles mosquitoes. During past decades, chloroquine and other aminoquinolines have been utilized as frontline antimalarial agents. However, an increase in drug resistance in Plasmodium falciparum has made it essential to develop new chemotherapeutic agents in addition to combination therapies utilizing available antimalarial drugs with different modes of action.1 Recently some specific polyether antibiotics have been reported to have potent antimalarial activity.25 K-41, a carboxylic acid containing polyether antibiotic produced from Streptomyces hygroscopicus. K-41, has been reported to exhibit nanomolar in vitro antimalarial activity against Plasmodium falciparum strains K1 (drug resistant) and FCR3 (drug sensitive).3 Furthermore, it showed high selectivity in vivo against both P. berghei strain N and P. yoelii strain NS infected mice, when administered orally.3 Several polyethers from this class, such as lonomycin A, nigericin, and monensin have been identified as potential antimalarial agents due to their highly potent and selective activity.4,5 These compounds classified as ionophores owe their potential activity to interact with ions (cations). A unique structural feature4,5,11 is that they possess a polycyclic alkyl backbone which confers lipophilic character to these compounds and a terminal carboxyl group which plays an important role in the formation of oxygen rich internal cavity which is capable of binding metal ions.11 Though rich in oxygen atoms, these molecules are lipophylic in nature. Since the parasite infected cell membrane is vulnerable to binding with lipophilic compounds, the putative mechanism of action for these polyethers is via transfer of ions through the membrane4, 5. This transport is potentially done after complexation of with a cation (mobile carrier: true isonophores) or by formation of trans-membrane channels (quasi-ionophores). Bacteria, especially Streptomyces sp. (isolated from soil samples) are reported as the primary producers of such molecules (with at least 21 producers strains reported thus far) 15. A literature evaluation has yield very little about the isolation of such compounds from marine Streptomyces sp: aplasmomycin12, arenaric acid, oxolonomycin13, 14

An antimalarial screening effort of marine microorganisms from Hawaiian sediments yielded a Streptomyces sp. designated strain H668 with highly potent in vitro activity against P. falciparum without significant cytotoxicity to Vero cells. The strain H668 was identified as a Streptomyces sp. on the basis of > 700 bp of sequence of the 16S rRNA gene. Bioassay-guided fractionation of the EtOAc-soluble fraction of the H668 culture led to the isolation of a new polyether metabolite. In this report, we describe the isolation and structure elucidation of this metabolite, and evaluate the antimalarial activity.

The antimalarial active fraction eluting with 70% MeOH in H2O using reversed phase C18 VLC, was further fractionated by preparative HPLC [Phenomenex C8 column (21.2 × 250 mm); flow rate 5 mL/min] using a gradient from 50% to 100% MeOH in H2O over 80 min. The active fractions were further purified by preparative HPLC [Phenomenex C18 column (21.2 × 250 mm at 5 mL/min] eluting with a gradient from 70% to 100% MeOH in H2O, to afford a semipure metabolite. Purification of this semipure compound by HPLC [5 micron C18 (10 × 250 mm); flow rate 3 mL/min] using an isocratic solvent of 75% MeOH in H2O, gave 3.0 mg of the pure metabolite 1.6

The 1H NMR spectrum of 1 indicated the presence of 11 oxymethines (3.1 – 4.3 ppm), 4 methoxy groups (3.2 – 3.6 ppm), 8 methyls (0.9 – 1.3 ppm), and methylenes (1.2 – 2.2 ppm). This was supported by the 13C and DEPT NMR spectroscopic data of 1. In addition, two oxygenated quaternary carbon signals at δC 82.8 and 78.4, as well as two ketal (or hemiketal) signals at δC 100.9 and 106.2 were observed in the 13C NMR spectrum. Four independent spin systems were identified by a COSY experiment, in which a sequential correlation from H-12 to H-23 and two methyl signals at the positions of C-26 and C-27 were observed, along with correlations for H-9 and H-10, H-3 through H-7, and H-1 and one methyl group at C-1. Several ambiguous correlations in the methylene area of the COSY data were identified based on the analysis of HSQC data. From the HSQC data, each protonated carbon for the partial structures could be assigned as shown in table 1. The HMBC data of 1 revealed correlations from H-12 (δH 3.89) to C-14 (δC 28.2) and C-15 (δC 81.7) and from H-15 (δH 3.74) to C-12 (δC 81.9), suggesting a structure of a furan ring (ring C). In a similar fashion HMBC correlations assisted in identifying ring D. Ring E was deduced from the HMBC analysis, where both the methyl protons at δH 0.97 (3H, d, J = 6.4 Hz, H-27) and 1.01 (3H, d, J = 6.4 Hz, H-26) showed correlations toward C-22 (δC 74.6), and the proton H-22 (1H, t, J = 10.0 Hz) exhibited 2- and 3-bond correlation with C-20 (δC 75.3), C-21 (δC 40.9), C-23 (δC 47.8), and C-24 (δC 100.9), along with a correlation from the methyl signal at δH 1.30 (3H, s, H-25) to C-24. Moreover, the HMBC correlations from H-12 to C-11 (δC 82.8) and C-10 (δC 94.8), as well as from neighboring protons (H-10, H-9, H-7, and H-6) to the ketal carbon at δC 106.2 facilitated the construction of a spiroketal analog linked with the ring C. Above results suggest that the compound 1 is a polyether type metabolite. Comparison of the NMR spectral data of 1 with those of polyether compounds previously reported supported the NMR assignments for the rings A – D.710 However, the residual part was quite different from any other polyethers reported thus far. The most significant difference is the lack of a carboxyl group in 1. COSY data confirmed the linkage of H-3 (δH 4.29, 1H, d, J = 10.0 Hz) and H-4 (δH 4.10, 1H, br s), and of H-1 (δH 3.45, 1H, m) and H-32 (δH 1.02, 3H, d, J = 6.4 Hz). The HMBC correlations from H-3 to C-2 (δC 78.4), as well as to the methyl carbon at δC 11.6 revealed the connection from C-1 to C-3 bearing two methyl groups (C-31 and C-32). In addition, two methoxyl groups at δH 3.54 and 3.39 were identified and attached at the position of C-1 and C-2, respectively by the HMBC data analysis. Taken together, the structure of 1 was determined as shown in figure 1, and all the 1H and 13C NMR data were assigned as in table 1. The relative configuration of 1 was determined on the basis of ROESY NMR data. NOE correlations were observed as described in table 1, which indicated that 1 has the same relative configuration in rings A–E as those of K-41 (figure 2).

Table 1.

NMR assignment of compound 1 in CD3OD

δCa δH mult. (J in Hz)b HMBC ROESY
1 81.8c 3.45, mc C-2, 1-OMe H-3
2 78.4 -
3 66.6 4.29, d (10.0) C-2, C-31 H-1, 2-OMe
4 61.4 4.10, br s
5 32.2 1.40, mc C-7
6 78.6 3.34, m C-4, C-8 H-7
7 36.7 1.71, m C-5, C-8, C-30 H-6, H-29, H-30
8 106.2 -
9 45.6 2.06, m C-8, C-10, C-29 H-10, H-29, H-30
10 94.8 3.43, d (9.6)c C-9, C-12, C-28, C-29, 10-OMe H-9, H-28, H-29
11 82.8 -
12 81.9c 3.89, t (7.2) C-10, C-11, C-14, C-15, C-28 H-13a, H-15, 10-OMe
13 26.0 1.99, m
1.83, mc
C-11, C-12, C-15 H-13a, H-14b, H-28
H-12, H-13b
14 28.2 1.71, mc
1.87, mc
C-12, C-15, C-16 H-13b, H-14a, H-16
H-14b, H-15
15 81.7 3.74, q (6.4) C-13, C-12 (or C-16), C-17 H-12, H-14a, H-16, H-17a
16 81.9c 3.99, q (6.4) C-14, C-19 H-14b, H-15, H-17b
17 28.5 2.06, m
1.83, mc
C-15, C-19 H-16, H-17a
H-15, H-17b, H-18a
18 24.8 2.00, m
1.91, mc
C-16, C-19, C-20 H-18a, H-21
H-17a, H-18b, H-20
19 79.9 4.20, dt (6.4, 2.8) C-20 H-20, H-27
20 75.3 3.40, mc H-18a, H-19, H-22, H-27
21 40.9 1.25, m C-19, C-20, C-22, C-27 H-18b, H-23, H-27
22 74.6 3.08, t (10.0) C-20, C-21, C-23, C-24, C-26, C-27 H-20, H-26, H-27
23 47.8 1.40, m C-22, C-24, C-25, C-26 H-21, H-25, H-26
24 100.9 -
25 21.2 1.30, s C-23, C-24 H-23, H-26
26 11.5 1.01, d (6.8)c C-22, C-23, C-24 H-22, H-23, H-25
27 12.3 0.97, d (6.4) C-20, C-21, C-22 H-19, H-21, H-22
28 24.7 1.37, s C-10, C-11 H-10, H-13b
29 10.5 0.97, d (6.4) C-9, C-10 H-7, H-9, H-10
30 12.0 0.95, d (6.8) C-6, C-7 H-7, H-9
31 11.6 1.10, s C-2 H-32
32 11.2 1.02, d (6.8)c C-1, C-2 H-31
1-OMe 60.0 3.54, s C-1
2-OMe 49.1 3.39, sc C-2 H-3
6-OMe 56.9 3.28, s C-6
10-OMe 59.6 3.41, s C-10 H-12
a

Assignments based on DEPT, HMQC, and HMBC NMR data (100 MHz).

b

Assignments based on COSY and HMBC NMR data (400 MHz).

c

Signals partially overlapped.

Figure 1.

Figure 1

Key HMBC correlations (→) and 1H-1H COSY data (—) for compound 1.

Figure 2.

Figure 2

Key NOE correlations (↔) for compound 1.

The antimalarial activity of the new metabolite (1) was evaluated against both the chloroquine-susceptible (D6) and -resistant (W2) clones of P. falciparum, and their toxicity was tested against Vero cells. Compound 1 showed antiprotozoal activity against both the D6 and W2 clones, with IC50 values ranging from 100 – 200 ng/mL. Although the in vitro antimalarial activity of 1 was significantly less than the original extract, no cytotoxicity was observed at 4.75 µg/mL, the highest concentration tested. The high index of selectivity (SI = IC50 Vero/IC50 P. falciparum) for 1 indicates that the polyether metabolite 1 is highly specific to the parasite. As discussed earlier the mechanism of action for ionophores (quasi-ionophore or mobile carrier) is via alteration of normal membrane permeability to cationic species.4,5,15 Ionophores (quasi-ionophore as a mobile carrier) have a unique structural feature which is crucial to their ability to interact with metal species such as Na+, K+, and Ca+.4,5,11 Some quasi-ionophores (alamethicin, gramicidin S, gramicidin D) are peptides or very large molecules and other mobile carrier are polycyclic polyethers compounds with an alkyl backbone, an internal oxygen rich pocket and a terminal carboxyl group. These last two features play an important role in their ability to binding metal ions.11 There are a number of examples of mobile carriers including: monensins A, B, C, nigericin, laidlomycin, grisorixin, mutalomycin, lonomycins A, B, X-206, alborixin, lenoremycin, dianemycin, carriomycin, septamycin, etheromycin, A-204A, K-41A, K-41B, and A-601612 all have a terminal carboxyl moiety15.

The new polyether 1 isolated from marine Streptomyces sp. H668 is not a typical ionophore or a member of either of these classes and structurally, it is clearly unrelated to the quasi-ionophores we came across in the literature. Though, it is closely related to several member of the mobile carrier group, the fact that it lacks the carboxyl functionality, suggesting the mode of action against the parasite warrants additional investigation. An important issue in antimalarial chemotherapy is resistance of P. falciparum to current drugs making it nessesary to identify new chemotherapeutic agents with unique structures and modes of action. Further investigations regarding mechanism of action studies and in vivo activity will be published in due course.

Supplementary Material

01. Supplementary Material.

Supplementary data (HRESIMS, 1H, 13C, and 2D NMR spectra) associated with this article can be found, in the online version.

Acknowledgments

The authors are grateful to the National Institute of Health (NIAID) 1RO1AI36596, National Center for Research Resources C06 RR-14503-01 and the Medicines for Malaria Venture for funding a predoctoral fellowship for Damaris A.F. Meujo.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, 2nd, Danis M, Greenwood BM, Anderson RM, Olliaro P. Lancet. 1999;353:1965. doi: 10.1016/s0140-6736(98)07367-x. [DOI] [PubMed] [Google Scholar]
  • 2.Otoguro K, Kohana A, Manabe C, Ishiyama A, Ui H, Shiomi K, Yamada H, Omura S. J. Antibiot. 2001;54:658. doi: 10.7164/antibiotics.54.658. [DOI] [PubMed] [Google Scholar]
  • 3.Otoguro K, Ishiyama A, Ui H, Kobayashi M, Manabe C, Yan G, Takahashi Y, Tanaka H, Yamada H, Omura S. J. Antibiot. 2002;55:832. doi: 10.7164/antibiotics.55.832. [DOI] [PubMed] [Google Scholar]
  • 4.Gumila C, Ancelin ML, Jeminet G, Delort AM, Miquel G, Vial HJ. Antimicrob. Agents Chemother. 1996;40:602. doi: 10.1128/aac.40.3.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gumila C, Ancelin ML, Delort AM, Jeminet G, Vial HJ. Antimicrob. Agents Chemother. 1997;41:523. doi: 10.1128/aac.41.3.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Compound 1: colorless solid, [α]D24 +48.2 (c 0.17, MeOH); HRESIMS m/z 711.4301 [M + Na]+ (calcd for C36H64O12Na, 711.4295).
  • 7.Seto H, Mizoue K, Otake N. J. Antibiot. 1980;33:979. doi: 10.7164/antibiotics.33.979. [DOI] [PubMed] [Google Scholar]
  • 8.Dorman DE, Hamill RL, Occolowitz JL, Terui Y, Tori K, Tsuji N. J. Antibiot. 1980;33:252. doi: 10.7164/antibiotics.33.252. [DOI] [PubMed] [Google Scholar]
  • 9.Dirlam JP, Bordner J, Cullen WP, Jefferson MT, Presseau-Linabury L. J. Antibiot. 1992;45:1187. doi: 10.7164/antibiotics.45.1187. [DOI] [PubMed] [Google Scholar]
  • 10.Cheng XC, Jensen PR, Fenical W. J. Nat. Prod. 1999;62:605. doi: 10.1021/np9801357. [DOI] [PubMed] [Google Scholar]
  • 11.Dorkov P, Pantcheva IN, Sheldrick WS, Mayer-Figge H, Petrova R, Mitewa M. J. Inorg. Biochem. 2008;102:26. doi: 10.1016/j.jinorgbio.2007.06.033. [DOI] [PubMed] [Google Scholar]
  • 12.Okami Y, Okazaki T, Kitahara T, Umezawa H. J. Antibiotics. 1976;29:1019–1025. doi: 10.7164/antibiotics.29.1019. [DOI] [PubMed] [Google Scholar]
  • 13.Cheng Xing C, Jensen Paul R, Fenical William. J. Natural Products. 1999;62(4):605–607. doi: 10.1021/np9801357. [DOI] [PubMed] [Google Scholar]
  • 14.Tsuji N, Nagashima K, Terui Y, Tori K. J. Antibiotics. 1979;32:169–171. doi: 10.7164/antibiotics.32.169. [DOI] [PubMed] [Google Scholar]
  • 15.Westley JW. Polyether Antibiotics: Naturally Occurring Acid, Ionophores. 1988;Vol. 1 [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01. Supplementary Material.

Supplementary data (HRESIMS, 1H, 13C, and 2D NMR spectra) associated with this article can be found, in the online version.

RESOURCES